The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...
Former CNET editor Dong Ngo has been involved with technology since 2000, starting with testing gadgets and writing code for CNET Labs' benchmarks. He managed CNET's San Francisco Labs, reviews 3D ...
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows ...
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback